HLA-A1 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
(MHC Class I, A cell surface antigen) | ||||||||||
About | ||||||||||
Protein | transmembrane receptor/ligand | |||||||||
Structure | αβ heterodimer | |||||||||
Subunits | HLA-A*01--, β2-microglobulin | |||||||||
Older names | HL-A1 | |||||||||
Subtypes | ||||||||||
|
||||||||||
Rare alleles | ||||||||||
|
||||||||||
Alleles link-out to IMGT/HLA database at EBI |
Subtype
|
allele
|
Available structures
|
---|---|---|
A1 | *0101 | 1W72 |
Subtype
|
allele
|
Available structures
|
---|---|---|
A1.2 | *0102 | |
A1.3 | *0103 |
Study population |
Freq. (in %) |
---|---|
Ireland South | 25.0 |
England Lancaster | 21.5 |
Wales | 21.1 |
Ireland Northern | 20.2 |
England Sheffield | 19.7 |
England Liverpool | 19.4 |
England Newcastle | 19.3 |
Spain Basque Arratia Vall… | 19.2 |
England Leeds | 19.1 |
England Manchester | 18.9 |
Australia New South Wales | 18.7 |
Australia West | 18.5 |
Scotland Orkney | 17.0 |
South Africa Natal Tamil | 17.0 |
Belgium | 15.5 |
Italy North (1) | 15.4 |
Israeli Jews | 15.2 |
France South East | 15.0 |
German Essen | 14.4 |
Russia Arkhangelsk Pomors | 14.0 |
Nador Metalsa (Berber) | 13.7 |
Sweden Stockholm | 13.6 |
Spain Basque Gipuzkoa Pro… | 13.5 |
Burkina Faso Fulani | 13.3 |
Pakistan Sindhi | 13.3 |
Serbia | 13.2 |
Portugal Centre | 13.0 |
Sweden Uppsala County | 13.0 |
Czech Republic | 12.7 |
India Andhra Pradesh Goll… | 12.5 |
Israel Gaza Palestinians | 12.4 |
India Mumbai Marathas | 12.3 |
Tunisia | 12.3 |
Algeria1 | 12.3 |
Romanian | 12.2 |
Italy | 12.1 |
Russia Northwest | 11.9 |
Kenya Nandi | 11.8 |
Spain Eastern Andalusia | 11.4 |
Macedonia (4) | 11.3 |
Tunisia | 11.2 |
Turkey (I) | 10.9 |
Spain North Cantabrian | 10.8 |
Greece North | 10.0 |
Croatia | 9.7 |
Italy South Campania | 9.7 |
Greece (3) | 9.2 |
Brazil | 9.1 |
Finland | 8.9 |
Saudi Arabia | 8.7 |
Spain Catalonia Girona | 8.6 |
Pakistan Karachi Parsi | 8.3 |
Uganda Kampala | 8.3 |
Mongolia Khalkha | 8.0 |
Jordan Amman | 7.9 |
Spain North Cabuernigo | 7.6 |
Kenya Luo | 7.4 |
Bulgaria | 7.3 |
Russia Chuvash | 7.3 |
Oman | 7.2 |
Singapore Javanese Indone… | 7.0 |
Georgia Tibilisi Kurds | 6.7 |
France Corsica | 6.5 |
Georgia Tibilisi Georgian… | 5.7 |
Georgia Svaneti Svans | 5.6 |
China Qinghai Hui | 5.5 |
Australian Aborigine Cape… | 5.3 |
Sudanese | 5.0 |
Italy Sardinia(3) | 4.5 |
Russia Murmansk Saomi | 4.0 |
Spain Pas Valley | 3.8 |
Zambia Lusaka | 3.5 |
Burkina Faso Rimaibe | 3.2 |
Singapore Riau Malay | 3.2 |
Kenya | 3.1 |
Russia Nenets | 3.1 |
Cameroon Bakola Pygmy | 3.0 |
Thailand | 2.8 |
Australian Aborigine Groo… | 2.7 |
Senegal Niokholo Mandenka | 2.7 |
Cameroon Bamileke | 2.6 |
India Jalpaiguri Toto | 2.5 |
China Shanghai | 2.4 |
Thailand Northeast | 2.4 |
Allele frequencies presented, only |
Study population |
Freq. (in %) |
---|---|
India North Delhi | 3.3 |
Kenya Nandi | 2.7 |
Cape Verde Southeastern I… | 1.6 |
Senegal Niokholo Mandenka | 1.6 |
Mali Bandiagara | 1.1 |
Tunisia | 1.0 |
Guinea Bissau | 0.8 |
Madeira | 0.8 |
USA African Americans (3) | 0.7 |
Argentina Toba Rosario | 0.6 |
USA Hispanic | 0.6 |
Kenya Luo | 0.4 |
Cameroon Beti | 0.3 |
Russia Tuva (2) | 0.3 |
Uganda Kampala | 0.3 |
Allele frequencies presented, only |
Study population |
Freq. (in %) |
---|---|
Israel Ashkenazi and Non … | 2.1 |
Kenya Nandi | 1.7 |
Sudanese | 1.5 |
Kenya | 0.7 |
Saudi Arabia Guraiat and … | 0.7 |
Iran Baloch | 0.6 |
Ch. Guangdong Meizhou Han | 0.5 |
China Beijing Shijiazhuan… | 0.2 |
Allele frequencies presented, only |
HLA-A1 (A1) is a human leukocyte antigen serotype within HLA-A "A" serotype group. The serotype is determined by the antibody recognition of α1 subset of HLA-A α-chains. For A1, the alpha "A" chain are encoded by the HLA-A*01 allele group and the β-chain are encoded by B2M . This group currently is dominated by A*0101. A1 and A*01 are almost synonymous in meaning. A1 is more common in Europe than elsewhere, it is part of a long haplotype that appears to have been frequent in the ancient peoples of Northwestern Europe. A1 is a frequent component of the AH8.1 haplotype. A1 serotype positivity is roughly linked to a large number of inflammatory diseases and conditions believed to have immune system involvement. Because of its linkage within the AH8.1 haplotype many studies showed association with A1 or A1,B8 only later to show the association drift toward the class II region gene alleles, DR3 and DQ2.5. While it is not clear what role A1 has in infectious disease, some linkage with infection rates in HIV remain associated within the A1 region of the haplotype.
In all instances so far, HLA-A1 has been found to be linked to disease by association, but there are few that define HLA-A1 has a predominant genetic risk relative to other gene-alleles in the vicinity of the A1 gene on the larger haplotype.
A1 serotype was associated with a number of diseases as "HL-A"' antigens were first being described. The associations rapidly expanded to include 'HL-A8' HLA-B8, as the HLA A1 and B8 were found to be commonly linked. As DRw3 was characterized, autoimmune risk drifted toward the class II region.
A1-B58 haplotype (A1-B17 where B58 is dominant) may remain associated with anti-neutrophil cytoplasmic antibody (ANCA)
With the exception of type 1 diabetes, most of the evidence for direct association of A1 with autoimmune diseases evaporated as DR3 and DQ2 genes were characterized. While type 1 diabetes shows an extended association on the HLA A1-B8-DR3-DQ2 haplotype, the association appears not to extend beyond the HLA-B locus. A recent study of DR3-DQ2/DR4-DQ8 phenotype found that A1-cw7-B8 was actually lower than expected relative to other A-B types, indicating that risk associated genes are located between B8 and DR3. However a study elsewhere showed that A*0101 appears to alter risk for type 1 diabetes but not Cw7-B8. The type 1 diabetes example shows the inherent difficulty in the use of linkage analysis alone to cipher risk.